Retrospective Study of the Level of HER2-Neu Gene Amplification as Predictive Factor of Response in Patients With HER2-Positive Advanced Breast Cancer Treated With Trastuzumab Containing Regimens.

At a glance
Trial Overview
Trial Details
- Identifiers
- Other Details
Interventions
Trial Centres
- Investigators
- Centres
Trial History
References

Trial Profile

Retrospective Study of the Level of HER2-Neu Gene Amplification as Predictive Factor of Response in Patients With HER2-Positive Advanced Breast Cancer Treated With Trastuzumab Containing Regimens.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab (Primary)
Indications Advanced breast cancer
Focus Pharmacogenomic; Therapeutic Use

Most Recent Events

02 Sep 2010 Biomarkers information updated
01 Sep 2010 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
17 Apr 2009 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com